Dr. Haitao Pan is an Associate Member in the Department of Biostatistics at St. Jude Children's Research Hospital. His research focuses on developing innovative statistical methods for clinical trial design, evidence generation, and treatment decision-making, particularly in pediatric oncology and rare cancers.
His methodological interests include Bayesian adaptive clinical trial designs, dose optimization, external controls, causal inference, and the integration of evidence from clinical trials and real-world data.
At St. Jude, he chairs the Clinical Trials Design Forum (CTDF), an institutional committee responsible for the early-stage scientific and statistical review of clinical trial concepts, and serves on the Clinical Trials Scientific Review Committee (CTSRC).
Dr. Pan also serves as a statistician for the New Approaches to Neuroblastoma Therapy (NANT) consortium and is a member of the PCDC International Neuroblastoma Risk Group (INRG) Committee. He holds adjunct faculty appointments at Florida State University and the University of Memphis.
He has authored more than 70 peer-reviewed publications, published a book with Springer Nature, and developed 18 R software packages supporting clinical trial design and statistical analysis.
Yuan Ji is Professor of Biostatistics at The University of Chicago. His research focuses on innovative Bayesian statistical methods for translational cancer research. He is the inventor of Bayesian adaptive designs such as the mTPI and i3+3 designs, which have been widely applied in dose-finding clinical trials worldwide. His work on cancer genomics was reported by numerous media outlets in 2015. He received the Mitchell Prize from the International Society for Bayesian Analysis in 2015 and is an elected Fellow of the American Statistical Association.
Senior Vice President, Clinical Research Administration
Comprehensive Cancer Center, Associate Director of Clinical
Research
Member, Department of Oncology
Dr. Fox leads clinical research prioritization, strategy, and operations at St Jude Children's Research Hospital. Nationally, she is the chair of Developmental Therapeutics Committee for the Children’s Oncology Group and the Pediatric Early Phase Clinical Trials Network. Dr. Fox has expertise in quantitative clinical and pre-clinical pharmacology, pediatric clinical oncology, and clinical research and trial design including response and toxicity biomarker endpoint development. She applies an integrative approach to clinical drug development utilizing animal models, pre-clinical and clinical pharmacology to evaluate new therapies and novel trial designs and improve outcome for children with catastrophic diseases.
Ryuma Tanaka, MD is a pediatric neuro-oncologist at Nationwide Children's Hospital and Assistant Professor of Pediatrics at The Ohio State University College of Medicine. His clinical and research interests focus on pediatric brain tumors, molecular diagnostics, precision oncology, immunotherapy and targeted therapies. He is involved in clinical trials and translational research aimed at advancing personalized treatment strategies and improving outcomes for children with central nervous system tumors.
Noriko Mitsuiki is a Specially Appointed Assistant Professor in Health Science Research and Development Center (HeRD) at Institute of Science Tokyo Hospital. She had been involved in the care of pediatric patients with cancer, hematologic diseases, and inborn errors of immunity as a pediatrician. She received her Ph.D. in Medicine from Tokyo Medical and Dental University in 2014. Before starting to work as a member of HeRD in 2026, she had 4 years of experience as a clinical reviewer in the Division of Oncology (New Drug V) at Pharmaceuticals and Medical Devices Agency (PMDA). She is currently interested in drug development for pediatric and rare disease patients.
Dr. Kentaro Takeda is a Senior Director, Head of innovative statistics at Astellas Pharma Global Development, Inc. His research interest covers Bayesian clinical trial designs, including dose-finding trials, basket trials, using real-world data, and oncology statistics. Dr. Takeda has published more than 70 peer-reviewed papers in the research area. Dr. Takeda is leading an innovative statistics group in Astellas and has implemented novel statistical approaches, including his proposed methods, in new drug developments. Dr. Takeda is also an associate editor of several academic journals.
Qian “Vicky” Wu is an Associate Professor of Biostatistics, Clinical Research Division at Fred Hutchinson Cancer Center. Vicky received her Ph.D. in Biostatistics at University of Pennsylvania and M.S. in Biostatistics at UCLA. Vicky’s research focuses on biomarker analysis, statistical genetics, and clinical trials, with particular emphasis on CAR-T immunotherapy studies. She has served as lead biostatistician for more than 30 CAR-T trials at Fred Hutch and Seattle Children’s. Her methodology work includes high-dimensional biomarker analysis for small sample size, survival analysis with time-varying covariates, and epigenetic data analysis. She also develops open-source R tools, including TrialSize, CNVtest, ChIPtest, Spacelog, HDI_Shiny, TVCurves, SampleN, etc, to make advanced methods more accessible to cancer researchers.
Dr. Luyan Dai possesses nearly two decades of industrial experience in healthcare and pharmaceutical industry in both US and Asia. She is a long term industry advocator and recognized advisor for applications of complex innovative designs, Bayesian analysis, multi-region clinical trials, real-world data and evidence, AI intelligent applications and digital technology in healthcare.
In her earlier years, she worked at Pfizer Global Research & Development Center and Boehringer Ingelheim Medicine in the US, contributing to global projects for clinical development and regulatory submissions in therapeutic areas including the central nervous system, hepatitis C, respiratory, oncology, cardiovascular, and women's health.
Dr. Dai was relocated to China in 2012 to establish the biostatistics function for Boehringer Ingelheim China and grew the team size from 1 to over 20 members. Later she successfully integrated the team in Japan and led the Asia team that contributed to the clinical development, regulatory submissions and market launch of nearly 30 product indications in Asia-Pacific, Middle East and Africa countries. She also enhanced the team’s global competencies to lead statistical distributions for global development programs.
Since she left Boehringer Ingelheim, she worked at two start-up companies and made significant contributions for the companies in IPO listings on the Hong Kong Stock Exchange. In 2018, she joined Harbour Biomed as the head of clinical research, contributed to the product development strategies, established and led the clinical team, facilitated external partnership alliances for clinical projects, and successfully delivered the key clinical project milestones to realize the strategic growth of the company.
In 2020, she joined Yidu Tech as the vice president of strategy and innovation with a dual role as the chief statistics expert, responsible for governing and upgrading the business and team of the life science sector, leading the exploration of new initiatives and breakthrough advancement of strategic projects, and supervising and overseeing the strategic partnership for key deliverables.
Dr. Dai also served as a venture capital partner of YD Capital. Dr. Dai received a Ph.D. in statistics from the University of Missouri, USA, specializing in Bayesian statistical methodology and application research. She graduated from Fudan University, majoring in statistics.